Jean-Philip Piquemal, co-founder and Chief Scientific Officer of deeptech company Qubit Pharmaceuticals, received the 2025 Honorary Award from France Quantum at its annual conference in Paris on June 10th. The award recognises Piquemal’s contribution to the quantum ecosystem and the establishment of Qubit Pharmaceuticals in 2020, originating from collaborative research between French and American university groups. Piquemal’s work at Qubit Pharmaceuticals focuses on accelerating drug discovery through quantum computing, notably the development of the Hyperion-1 emulator and FeNNix-Bio1, a foundation model for molecular simulation. He maintains a position as professor at Sorbonne University and director of the Laboratoire de Chimie Thorique (Sorbonne University/CNRS).
Qubit Pharmaceuticals pioneers a new era in drug discovery, leveraging the power of quantum computing and artificial intelligence to accelerate the development of novel therapeutics. The company builds upon fifteen years of collaborative research between French and American university groups, deliberately addressing limitations inherent in conventional drug discovery processes. Success hinges on demonstrating a clear return on investment for partners, achieved through reduced development times and improved therapeutic efficacy.
Researchers utilise the company’s platform to identify promising drug candidates, predict their efficacy, and optimise their design. This accelerates the pace of innovation and brings new therapies to market faster. Qubit Pharmaceuticals actively fosters open innovation, cultivating a structure that encourages collaboration and knowledge sharing with industry partners.
The company strategically centres its operations on collaborative
The company strategically centres its operations on collaborative partnerships with pharmaceutical and biotechnology companies, offering its advanced simulation capabilities to accelerate their research and development pipelines. This collaborative approach allows partners to leverage cutting-edge technology without significant capital investment, accelerating the pace of innovation. This business model positions Qubit Pharmaceuticals as a specialized technology provider, seamlessly integrating its services into existing drug discovery workflows.
Qubit Pharmaceuticals distinguishes itself through a dual-pronged approach, employing both the Hyperion-1 emulator and the FeNNix-Bio1 foundation model to tackle distinct challenges in pharmaceutical research. Hyperion-1 offers a practical solution by enabling the execution of complex algorithms on readily available computational resources, bypassing the need for fully realised quantum hardware. FeNNix-Bio1, conversely, represents a significant advancement in computational modelling, providing a powerful tool for simulating molecular interactions with unprecedented accuracy and speed.
The Hyperion-1 emulator and FeNNix-Bio1 foundation model address distinct challenges, working in synergy to accelerate drug discovery. Hyperion-1 circumvents current limitations in quantum hardware, enabling the execution of complex algorithms on existing computational infrastructure. FeNNix-Bio1 functions as a large-scale AI model, trained on extensive molecular data to simulate molecular interactions with unprecedented detail and speed.
Jean-Philip Piquemal spearheads this innovation, translating scientific breakthroughs into practical applications and fostering a commitment to interdisciplinary collaboration. Piquemal’s career exemplifies a dedication to bridging the gap between theoretical research and real-world impact, establishing a foundation at Sorbonne University and expanding his expertise at the National Institute of Environmental Health Sciences. This transatlantic experience cultivated a unique perspective, integrating the rigor of French academic tradition with the dynamic methodologies of American research.
Piquemal’s leadership underscores the importance of interdisciplinary collaboration
Piquemal’s leadership underscores the importance of interdisciplinary collaboration and the need for scientists to actively engage with the challenges of bringing new technologies to market. He champions a model of academic spin-off, coupled with strategic industry partnerships, recognising this as a key driver of innovation in the pharmaceutical sector. Piquemal’s vision extends beyond technological advancement, encompassing a commitment to societal impact and improving human health.
This commitment extends beyond mere technological integration, encompassing a shared vision for transforming the drug discovery landscape. Qubit Pharmaceuticals actively cultivates a network of partnerships with pharmaceutical and biotechnology companies, offering its simulation capabilities to streamline their research and development processes.
External Link: Click Here For More
